Results 11 to 20 of about 15,580 (252)

What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study. [PDF]

Br J Dermatol, 2021
Multiple strategies have been used to evaluate the minimal important change (MIC) of the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD). The meaningfulness of these MICs is not well established across all severities of atopic dermatitis (AD).To determine the MIC of percentage and absolute improvement of EASI and SCORAD ...
Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, Chavda R, Gabriel S, Patel KR, Singam V, Kantor R, Hsu DY.   +11 more
europepmc   +6 more sources

Assessment of the severity of atopic dermatitis [PDF]

Przegląd Dermatologiczny, 2016
Atopic dermatitis is a frequent, chronic and recurrent inflammatory skin disease with complex etiology. Typical symptoms of this disease are persistent itching and dry skin.
Agnieszka Bożek, Adam Reich
doaj   +2 more sources

Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores [PDF]

Journal of the European Academy of Dermatology and Venereology, 2023
AbstractBackgroundBaricitinib treatment in adults with moderate‐to‐severe atopic dermatitis (AD) has demonstrated rapid improvements in itch as well as AD sign severity and affected body surface area as assessed by the Eczema Area and Severity Index (EASI) total score, whether administered as monotherapy or in combination with topical corticosteroids ...
Wollenberg, Andreas, Simon, Dagmar, Kulthanan, Kanokvalai, Figueras-Nart, Ignasi, Misery, Laurent, Tangsirisap, Nithi, Spina, Lara, Lu, Na, Grond, Susanne, Eyerich, Kilian   +9 more
core   +8 more sources

Diagnosis, assessment, and treatment of childhood eczema in primary care: cross-sectional study [PDF]

BJGP Open, 2017
Background: The majority of children with eczema in the UK are looked after in primary care yet we know little about their care in this setting. Aim: To compare the diagnosis, assessment, and treatment of eczema in primary care with published diagnostic ...
Laureen Jacquet, Daisy M Gaunt, Kirsty Garfield, Matthew J Ridd   +3 more
doaj   +2 more sources

EXACERBATED ECZEMA: ROLE OF BUILT ENVIRONMENT IN INCREASING DISEASE SEVERITY AMONG PAKISTANI PATIENTS [PDF]

Pakistan Journal of Medicine and Dentistry, 2019
Atopic Eczema is a non-contagious skin disease. This study was undertaken to determine the role of home environment allergens in aggravation of atopic eczema by using EASI (Eczema Area And Severity Index) and POEM (Patient Oriented Eczema Measure ...
Bisma Laeeque, Muhammad Laeeque, Zirgham Masood, Muhammad Ijaz Ahmed   +3 more
doaj   +2 more sources

A clinical trial for evaluation of leech application in the management of Vicarcikā (Eczema)

Ancient Science of Life, 2014
Background: Skin diseases are among the most common health problems worldwide and are associated with a considerable burden. Eczema is such a skin ailment which cause psychological, social and financial burden on the patient and their families ...
K M Pratap Shankar, S Dattatreya Rao, Shaik Nafeez Umar, V Gopalakrishnaiah   +3 more
doaj   +2 more sources

Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24

Italian Journal of Dermatology and Venereology, 2022
In multiple phase 3 trials, dupilumab improved signs, symptoms (including pruritus), and quality-of-life (QoL) in adults with moderate-to-severe atopic dermatitis (AD). In Italy, dupilumab received innovation status but is currently only reimbursed by the National Health Service for adults with Eczema Area Severity Index (EASI) scores ≥24.
Offidani, Annamaria, Stingeni, Luca, Neri, Iria, Cipriani, Filippo, Chen, Zhen, Rossi, Ana B, Lu, Yufang, Moretti, Devis   +7 more
openaire   +4 more sources

The Eczema Area and Severity Index-A Practical Guide. [PDF]

Dermatitis, 2022
Atopic dermatitis is a chronic inflammatory skin condition that affects approximately 18 million people in the United States. Assessing the extent and severity of atopic dermatitis is critical for determining baseline disease burden and treatment effectiveness for both investigators and clinicians.
Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL.   +5 more
europepmc   +3 more sources

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. [PDF]

Dermatol Ther (Heidelb)
Atopic dermatitis (AD) affects multiple areas of the body, some of which may be more refractory to treatment. We evaluated improvements in the Eczema Area and Severity Index (EASI) by body region and clinical signs for each body region in lebrikizumab-treated patients with moderate-to-severe AD.ADvocate 1 and ADvocate 2 compared lebrikizumab 250 mg as ...
Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI.   +14 more
europepmc   +10 more sources

Vitamin D deficiency and atopic dermatitis severity in a Bangladeshi population living in East London: A cross‐sectional study

Skin Health and Disease
Background Atopic eczema is a common, chronic, inflammatory skin condition with considerable heterogeneity. South Asian people living in the UK frequently have low serum vitamin D3 (25(OH)D3), and those with atopic disease can present with severe eczema.
Rebecca L. McCarthy, Soha S. Tawfik, Ioannis Theocharopoulos, Ravinder Atkar, Bryan McDonald, Sasha Dhoat, Aaron Hughes, Bjorn R. Thomas, Edel A. O’Toole   +8 more
doaj   +2 more sources